💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Peginterferon Alfa-2A

CHEMBL1201560 Phase 4 Одобрено Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A long-acting interferon used to treat chronic hepatitis C and hepatitis B infections by boosting the immune system's ability to fight the virus and slow its replication. It is administered once weekly by injection and may be combined with other antiviral medications.

Терапевтические области

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Endocrinology Pain Management Non-Small Cell Lung Cancer Generalized Anxiety Disorder Non-Alcoholic Fatty Liver Disease Lymphoma Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A long-acting interferon used to treat chronic hepatitis C and hepatitis B infections by boosting the immune system's ability to fight the virus and slow its replication. It is administered once weekly by injection and may be combined with other antiviral medications.

Yes, Peginterferon Alfa-2A is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201560. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.